Evidence map›Paper›PMID 31339892›Full record

Trial reportPloS one2019

Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.

Daniel F Fleischmann, Marcus Unterrainer, Stefanie Corradini, Maya Rottler, Stefan Förster, Christian la Fougère, Timo Siepmann, Markus Schwaiger, Peter Bartenstein, Claus Belka and 2 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Daniel F FleischmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-5493-0620
Marcus UnterrainerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Stefanie CorradiniDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Maya RottlerDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Stefan FörsterDepartment of Nuclear Medicine, Klinikum Bayreuth, Bayreuth, Germany.
Christian la FougèreDepartment of Nuclear Medicine and Clinical Molecular Imaging, University of Tuebingen, Tuebingen, Germany.
Timo SiepmannCenter for Clinical Research and Management Education, Division of Health Care Sciences, Dresden International University, Dresden, Germany.
Markus SchwaigerDepartment of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Peter BartensteinGerman Cancer Consortium (DKTK), partner site Munich, Munich, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Claus BelkaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Nathalie L AlbertGerman Cancer Consortium (DKTK), partner site Munich, Munich, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maximilian NiyaziDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
German Cancer Research Center · DELMU Klinikum · DEBayreuth Medical Center · DEDresden International University · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe advantage of combined PET-MRI over sequential PET and MRI is the high spatial conformity and the absence of time delay between the examinations. The benefit of this technique for planning of re-irradiation (re-RT) treatment is unkown yet. Imaging data from a phase 1 trial of re-RT for recurrent glioma was analysed to assess whether planning target volumes and treatment margins in glioma re-RT can be adjusted by PET-MRI with rater independent PET based biological tumour volumes (BTVs). PATIENTS AND

methodsCombined PET-MRI with the tracer O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) prior to re-RT was performed in recurrent glioma patients in a phase I trial. GTVs including all regions suspicious of tumour on contrast enhanced MRI were delineated by three experienced radiation oncologists and included into MRI based consensus GTVs (MRGTVs). BTVs were semi-automatically delineated with a fixed threshold of 1.6 x background activity. Corresponding BTVs and MRGTVs were fused into union volume PET-MRGTVs. The Sørensen-Dice coefficient and the conformity index were used to assess the geometric overlap of the BTVs with the MRGTVs. A recurrence pattern analysis was performed based on the original planning target volumes (PTVs = GTV + 10 mm margin or 5 mm in one case) and the PET-MRGTVs with margins of 10, 8, 5 and 3 mm.

resultsSeven recurrent glioma patients, who received PET-MRI prior to re-RT, were included into the present planning study. At the time of re-RT, patients were in median 54 years old and had a median Karnofsky Performance Status (KPS) score of 80. Median post-recurrence survival after the beginning of re-RT was 13 months. Concomitant bevacizumab therapy was applied in six patients and one patient received chemoradiation with temozolomide. Median GTV volumes of the three radiation oncologists were 35.0, 37.5 and 40.5 cubic centimeters (cc) and median MRGTV volume 41.8 cc. Median BTV volume was 36.6 cc and median PET-MRGTV volume 59.3 cc. The median Sørensen-Dice coefficient for the comparison between MRGTV and BTV was 0.61 and the median conformity index 0.44. Recurrence pattern analysis revealed two central, two in-field and one distant recurrence within both, the original PTV, as well as the PET-MRGTV with a reduced margin of 3 mm.

conclusionPET-MRI provides radiation treatment planning imaging with high spatial and timely conformity for high-grade glioma patients treated with re-RT with potential advancements for target volume delineation. Prospective randomised trials are warranted to further investigate the treatment benefits of PET-MRI based re-RT planning.

Indexed as

Brain NeoplasmsChemoradiotherapyGliomaMagnetic Resonance ImagingPositron-Emission TomographyAdolescentAdultAgedBevacizumabFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalTemozolomideTumor Burden(18F)fluoroethyltyrosineBevacizumabTemozolomideTyrosine

Identifiers

PMID31339892
PMCPMC6655559
OpenAlexW2963612094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.